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Neuropsychiatric symptoms in multiple sclerosis 
 
Andrew Sommerlad MBBS, BSc, MRCPsych, Gary Price MBChB, MRCPsych, MSc, PhD, Anand Trip 
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Multiple sclerosis is associated with a high prevalence of psychiatric comorbidity, including 
affective, psychotic and cognitive disorders. In this review, Dr Sommerlad and colleagues discuss 
the epidemiology, aetiology and management of neuropsychiatric symptoms in multiple sclerosis, 
using case vignettes to demonstrate the wide range of clinical presentations. 
 
Introduction 
 
Multiple sclerosis (MS) is the commonest cause of neurological disability in young and middle-aged 
adults1. The characteristic pathological features are demyelinating plaques, astrocytic gliosis and 
immune-mediated inflammation anywhere within the central nervous system, with the 
periventricular region, brainstem, juxtacortical region, optic nerves and spinal cord being particularly 
common targets. The neurological manifestations are diverse although usually reflect the function of 
the affected anatomical site, and the course of the illness is variable and initially difficult to predict 
with accuracy. 
 
In 80-90% of cases, the illness is relapsing-remitting in nature with two thirds of these developing a 
secondary progressive form of the condition a variable number of years after onset and a third 
having a relapsing-remitting course which does not result in long-term serious disability; the 
remaining 10-20% of patients have a primary progressive course with gradually worsening 
symptoms2. The prognosis can be poor in the long-term but progression is frequently slow; recent 
evidence suggests a median of 28 years before a stick is required for walking3. 
 
The UK annual incidence of MS is 10/100,000 with a prevalence of 200/100,0004. There is estimated 
to be over 100,000 people suffering from the condition in the UK. The median age of onset is 31 
years and it is approximately twice as common in women5. There is multifactorial aetiology with 
genetic and environmental factors shown to be important. There is 31% monozygotic concordance 
compared to 5% in dizygotic twins6 while the environmental influence is demonstrated by marked 
variations in prevalence in genetically homogenous populations7. Prevalence increases with 
increasing distance from the equator and those who emigrate in childhood have prevalence rates 
consistent with their adopted country.8 
 
MS commonly presents with weakness, tingling or numbness in the limbs; diplopia, visual loss or 
impaired visual acuity; vertigo; dysarthria and ataxia; fatigue or bladder and bowel disturbance5. The 
array of presenting symptoms in MS can lead to diagnostic uncertainty and neuropsychiatric 
conditions such as somatisation disorder are sometimes suspected. A study demonstrated that 16% 
of patients with MS had been referred to a psychiatrist between the onset of neurological symptoms 
and diagnosis of MS. In spite of neurological symptoms being present in the majority of cases, these 
remained largely overlooked and diagnoses of conversion disorder and hysterical personality 
disorder were applied9. While neurological features are the most recognised manifestations of the 
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condition, psychopathology, including affective, psychotic and cognitive disorders, is also common in 
MS. The identification of these symptoms is often more difficult and diagnosis can be delayed. 
Psychiatric symptoms can occur at onset or later in the MS disease process and initial psychiatric 
symptoms tend to improve later than neurological symptoms and frequently never resolve10. 
 
In this review article, we will describe a range of neuropsychiatric disorders which can develop in MS, 
illustrated by case vignettes from our clinical practice, and consider the most appropriate 
management. 
 
Mood disorders 
Depression 
 
Case vignette 1 – Major depressive disorder 
Andrea is a 45 year old woman with a 5 year history of relapsing-remitting MS with limb sensory deficit being the 
predominant feature. She presented with three month history of low mood, reduced motivation and feelings of 
hopelessness associated with suicidal thoughts. Cognitive assessment was normal and treatment with sertraline 100mg 
daily and cognitive behavioural therapy was initiated with good therapeutic effect at four month follow-up. 
 
Depressive symptoms are common in patients with significant disability but distinction should be 
made between sufferers with these symptoms and those with the syndrome of major depression, 
which is characterised by pervasive mood change, diurnal mood variation, altered sleep and appetite 
and distorted beliefs including feelings of guilt and worthlessness and suicidal ideation. The lifetime 
prevalence of major depression in MS, replicated in a number of studies, is around 50% with a point 
prevalence of 14%11, which is higher than matched populations with non-neurological disability and 
around three times higher than the general population. 
 
Due to the potential overlap between somatic symptoms of depression and features of MS, 
clinicians should use a screening tool which gives weight to depressive thoughts to identify patients 
at risk of depression that warrant more detailed clinical interview. The Beck Depression Inventory12 
and Hospital Anxiety and Depression Scale13 are suitable and have been validated for patients with 
MS. 
 
The identification of depression in people with MS is important as it is linked with lower quality of 
life, more functional impairment, poor cognitive function and reduced adherence to medication 
regimes14 as well as higher rates of suicide than the general population. Suicidal ideation is common 
in MS with a quarter of patients considering suicide at some point during their illness. Young males 
within five years of diagnosis are at highest risk of completed suicide while presence and severity of 
depression, social isolation and alcohol abuse are other notable risk factors13. 
 
Biological and psychosocial factors are implicated in the aetiology of depression in MS. Evidence 
suggests that the individual’s adjustment to adversity and their coping strategies is more closely 
related to physical deterioration than the severity of depression; loss of recreational opportunities 
and poor quality relationships are also important15. Studies have not demonstrated significant 
correlation between depression and plaque load16 but the location of lesions is significant. A higher 
lesion load in the anterior temporal lobe and inferior medial prefrontal cortex of the dominant 
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hemisphere as well as dominant anterior temporal lobe atrophy are associated with depression17. 
Genetic factors have not been shown to be relevant, while some have proposed that dysfunction in 
the hypothalamic-pituitary-adrenal axis underlies the increased risk of depression in MS. 
 
There has been some concern in the past that the use of disease-modifying drugs (DMDs), 
particularly interferon-β, resulted in increased risk of depression and suicide. However, recent 
evidence has suggested that this is not the case and the value of interferon in maintaining remission 
in MS means that it should remain a treatment option in all individuals, including those with a past 
history of depression, but used with caution in those with severe depression. It is appropriate to 
screen high-risk individuals for depression following the initiation of treatment with DMDs and, if 
depression develops, the agent need not be stopped automatically, but depression should be 
treated using standard options18. 
 
Several treatment options seem to be effective in treating depression in MS but the strength of 
evidence for any particular treatment is poor. Although open label trials and case-reports suggest 
efficacy of many different antidepressants in the treatment of depression in MS, there have been 
only two previous blinded randomised-controlled trials (RCT), of desipramine19 and paroxetine20, 
which have shown only a non-statistically-significant trend towards improvement in the drug groups 
compared to placebo. Electroconvulsive therapy (ECT) shows efficacy in severe depression but can 
result in exacerbation of symptoms of MS21. Results from trials of individual or group psychological 
treatments have shown more promise and cognitive-behavioural therapy (CBT) can be helpful in 
mild-moderate depression and as effective as treatment with the antidepressant sertraline22. A well-
conducted RCT of telephone-administered CBT compared to a control group of supportive therapy 
by telephone demonstrated a significant reduction in cases of depression and depressive symptoms 
after therapy but the difference between the groups were no longer significant at one year follow-
up23. 
 
Treatment of depression in MS remains difficult and is poorly guided by evidence but the Golman 
Consensus Group recommends individualised treatment of moderate-severe depression with a 
combination of an antidepressant and a form of psychotherapy, either supportive, CBT or 
interpersonal therapy14. 
 
Bipolar affective disorder 
 
Co-occurrence of bipolar affective disorder (bipolar disorder) and MS is uncommon but prevalence 
of bipolar disorder in people with MS is at least double the expected rate24 and a number of 
potential explanations have been proposed although none fully explain the association. Some can be 
attributed to the mania-inducing properties of steroids but a shared genetic diathesis has also been 
proposed25. White matter hyperintensities are often reported in patients with bipolar disorder but 
these are not always seen and their aetiology is unclear. However, a study of patients with psychosis 
in MS demonstrated a predominance of plaques bilaterally in the temporal horn areas – this was 
common to both affective and schizophrenia-like presentations26. 
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Management of bipolar disorder in MS is not guided by robust evidence but lithium and sodium 
valproate have previously been used with success. The diuretic effect of lithium in patients prone to 
bladder pathology and the potential for additional neurological impairment from lithium toxicity, 
however, necessitates caution in this patient group. The administration of exogenous steroids 
remains a mainstay of treatment in MS but care should be taken in those with a personal or family 
history of depression. The proven efficacy of lithium as prophylaxis against steroid-induced mania27 
suggests that careful monitoring of mental state on a reduced steroid dose, along with the addition 
of lithium, is likely to prove effective if a manic episode occurs during treatment. 
 
Disorders of affect 
Pseudobulbar affect 
 
Pseudobulbar affect (PBA), synonymous with the condition of pathological laughing and crying, is 
characterised by uncontrollable laughing and/or crying without the associated subjective feelings of 
happiness or sadness and usually without any discernable stressor. PBA is socially and occupationally 
disabling and distressing for patients and their families. It is seen in around 10% of MS patients and 
is associated with long disease duration, a progressive course, cognitive impairment and greater 
physical disability28. PBA is also seen in other neurological conditions, including Parkinson’s Disease, 
Motor Neurone Disease and stroke. Cognitive assessment usually demonstrates poor performance 
on tasks involving prefrontal function. Structural brain changes predict pseudobulbar affect29; 
bilateral medial inferior frontal and bilateral parietal hyperintense lesions and brainstem 
hypointense lesions are seen. 
 
Use of the Centre for Neurologic Study Emotional Lability Scale, a seven-item self report tool, is 
recommended for screening12. While treatment with small doses of amitriptyline, fluoxetine or 
levodopa has previously shown some benefit, new guidelines from the American Academy of 
Neurology propose the use of a combination of dextromethorphan and quinidine, which were 
shown in two RCTs to reduce emotional lability and significantly improve quality of life12. 
 
Euphoria 
 
Case vignette 2 – Euphoria 
Jane, a 22 year old woman with secondary progressive MS characterised by optic neuritis and limb weakness, presented to 
neurology outpatient clinic with her mother who was concerned about her inappropriate public behaviour; she would 
react with extreme excitement to unremarkable situations. She was inappropriate and incongruously optimistic during 
assessment while neuropsychological assessment showed mild frontal and subcortical deficit. Symptomatic treatment with 
sodium valproate yielded little benefit. 
 
In possibly the earliest large study of neuropsychiatric problems in MS in 1926, Cottrell and Kinnier 
Wilson reported the presence of euphoria in 63 of 100 consecutive cases of disseminated sclerosis at 
Queen Square30, although recent studies have suggested prevalence in MS sufferers to be around 
10%31. Euphoria should not be confused with hypomania or mania seen in bipolar affective disorder. 
It is a fixed mental state change (rather than fluctuating as seen in mania) distinguished by 
unconcern over physical disability and incongruous optimism and is associated with more severe MS, 
greater physical disability, cognitive dysfunction, lack of insight and a severe, often frontal, brain 
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lesion load. It is seen in around 10% of MS sufferers and is likely to be related to impairment of the 
self-regulatory orbito-frontal network. 
 
Psychotic disorders 
 
Case vignette 3 – Psychotic episode 
Simon is a 26 year old man who presented to the emergency department following two possible seizures and 
encephalopathy. He became emotionally labile and developed persecutory delusional ideas that he was the target of a 
conspiratorial plot. The addition of risperidone 2mg BD was effective in controlling these symptoms. MRI brain showed 
multiple white matter lesions in the corpus callosum and temporal horns which enhanced with gadolinium and CSF analysis 
revealed oligoclonal bands. The initial diagnosis was possible acute disseminated encephalomyelitis but treatment with 
interferon-beta was initiated after a year when he developed a sensory spinal cord syndrome characteristic of MS. 
 
Although psychosis in people with MS is a rare occurrence, studies suggest that the prevalence rate 
surpasses that expected by chance32. The reason for this is unclear; it may be due to direct effect of 
demyelinating lesions as patients with MS and psychosis are more likely to have plaques affecting 
the temporal horns bilaterally26 although a viral precursor to both conditions has also been proposed. 
 
Affective and schizophrenia-like presentations are seen equally when MS patients become psychotic 
but the predominant presentation is one of positive psychotic symptoms (usually persecutory 
delusions) with relative lack of negative symptoms (apathy, restricted affect and thought26). In 
addition, compared to schizophrenia, MS-related psychosis tends to present later (mean age around 
36 years) and there is quicker resolution of symptoms, fewer psychotic relapses and a better long-
term outcome with 60% of patients having only one psychotic episode over six year follow-up26. 
 
The evidence to favour a particular antipsychotic is scarce but atypical agents are preferred due to 
lower risk of adverse neurological effects; olanzapine, quetiapine and risperidone. As irritability and 
agitation is common in people with MS and psychosis, hospital admission is sometimes required and 
benzodiazepines are appropriate if added sedation is required. 
 
Cognitive Disorders 
 
Case vignette 4 – Cognitive impairment 
Derek, a 20 year old man with a five year history of relapsing-remitting MS, was admitted to neuropsychiatry ward due to a 
two month history of disorganised behaviour at home. During assessment, his behaviour was bizarre at times and he 
displayed fixed, concrete thinking and impaired attention. He scored 30/30 on MMSE but was slow to answer some aspects 
of this screen. Formal neuropsychological testing demonstrated significant impairment in executive functioning and 
information processing speed with reduced naming and facial recognition. 
 
Cognitive deficit in MS was described by Charcot in 1877 who noted that MS causes ‘marked 
enfeeblement of the memory, conceptions are formed slowly and intellectual and emotional 
faculties are blunted in their totality’33. Slowed cognitive processing is present early in the disease 
and can be seen in people with clinically isolated syndromes – a single episode of demyelination in 
one area of the central nervous system, eg optic neuritis or brainstem or spinal cord syndrome – 
who had asymptomatic lesions elsewhere in the brain on Magnetic Resonance Imaging (MRI)34. In 
people with established MS, around 40% have cognitive abnormalities35. Risk factors for impaired 
cognitive function in MS are age greater than 40 years, low premorbid intelligence or educational 
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attainment and depression and cognitive impairment tends to develop alongside worsening physical 
disability, disease duration and the onset of a progressive disease course35. Patients with a relapsing-
remitting disease course generally perform better than those with progressive illness in whom the 
predominant deficit is executive function, rather than memory which is affected in relapsing 
remitting disease36. 
 
Cognitive dysfunction adversely affects daily functioning, employment and quality of life and is 
frequently missed in routine assessment; when a neurologist suspects cognitive impairment, they 
are correct in over 90% of cases but when they do not suspect cognitive impairment, they are wrong 
in half of cases37. Thorough neuropsychological assessment is time-consuming and costly so 
approaches have been proposed to assess those in greatest need. The Mini-Mental State 
Examination is not useful in screening MS patients for cognitive impairment but screening using the 
Multiple Sclerosis Neuropsychological Screening Questionnaire37, a 15-item self- or informant-rated 
measure of cognitive and neuropsychiatric problems which has been validated for use in MS, may be 
a helpful strategy. More thorough assessment using a battery of neuropsychological tests which 
assess the cognitive domains most affected in MS patients (processing speed, learning and memory, 
executive function, visuospatial processing and word retrieval) is recommended for people in whom 
cognitive dysfunction is suspected; the Minimal Assessment of Cognitive Function in MS battery is a 
valid approach to neuropsychological assessment in MS patients38. 
 
MS has been suspected of causing a subcortical pattern of cognitive deficit (ie forgetfulness, 
emotional or personality changes, slowed thought processes and impaired executive function) as it 
affects classic subcortical white matter tracts such as periventricular white matter tracts and the 
corpus callosum and this has been borne out by research; information processing speed, verbal 
memory, cognitive flexibility and executive function are all impaired39.  
 
The presentation of cognitive deficit in MS is variable. Cognitive function tends not to vary with 
other markers of relapse and remission and the syndrome of a rapidly progressive dementia is rare 
but there is usually a progressive course with more cognitive domains affected, and correlation with 
markers of physical disability and social dysfunction40. Some patients can present with predominant 
severe cognitive impairment without significant impairment in other neurological domains and in 
these patients, brain atrophy is commonly seen on neuroimaging and DMDs are frequently 
ineffective41. 
 
Cognitive impairment can be predicted on traditional MRI imaging by brain atrophy but not by the 
degree or location of demyelinating lesions42 although more advanced MRI techniques are showing 
more promise in this regard. The combination of structural and functional MRI imaging has 
demonstrated altered cerebral activation in MS patients performing as well as controls on tasks 
requiring attention while MS patients who performed worse on a planning ability task did not have 
abnormal brain activation, suggesting that compensatory mechanisms related to neuronal plasticity 
can mitigate the pathological changes but can become overwhelmed, leading to the manifestation of 
cognitive symptoms35. There is also increasing evidence that grey matter pathology, reflected by 
atrophy, is implicated in cognitive dysfunction as MS progresses43. 
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DMDs are the first-line of treatment for MS and secondary outcome data from some large RCTs have 
demonstrated that early treatment with interferon beta results in better processing speed and 
working memory44 but no RCTs have assessed this as a primary outcome so the methodology does 
not allow sound conclusions to be drawn. Initial enthusiasm for the use of acetyl-cholinesterase 
inhibitors or memantine, which are used in dementia, has dispersed as they have been shown to be 
ineffective45. Symptomatic treatment with the stimulants L-amphetamine and methylphenidate 
have been proposed by some authors but this is controversial46. 
 
Of non-pharmacological treatments, cognitive rehabilitation is likely to be the most effective and has 
two components; restoration of function and compensation for loss of function. Relying on neuronal 
plasticity, restorative approaches aim to identify specific cognitive deficits and introduce remedial 
therapies to increase performance in a given area, such as graded practice for improving memory. 
Compensatory strategies aim to maximise the use of the retained cognitive abilities in order to 
improve social and occupational function, such as using notebooks or calendars to record important 
information or appointments and developing time management skills35. 
 
Conclusions 
An understanding of neuropsychiatric disorders in MS is important for all professionals involved in 
the care of people with MS. These disorders occur early in the disease, affect about half of patients 
at some point and have a significant impact on social/occupational function and quality of life. 
Furthermore, they negatively affect patients’ ability to adhere to the recommended treatment 
regimens for other neurological symptoms in MS. Timely detection is essential as therapies can often 
be successful and improve quality of life, although the paucity of empirical treatment data 
demonstrates the need for targeted research on the management of these disorders. 
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Figures 
Table 1 
Useful Assessment Schedules 
Depression Beck Depression Inventory, Hospital Anxiety and Depression Scale 
Pseudobulbar Affect Centre for Neurologic Study Emotional Lability Scale 
Cognitive function Screening Multiple Sclerosis Neuropsychological Screening Questionnaire 
Neuropsychological assessment Minimal Assessment of Cognitive Function in MS 
 
Table 2 
Treatment options in multiple sclerosis 
Depression Sertraline, CBT 
Mania Lithium, Sodium valproate 
Pseudobulbar palsy Dextromethorphan and Quinidine 
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Psychosis Olanzapine, Quetiapine, Risperidone 
Cognitive impairment Disease modifying drugs. Cognitive rehabilitation 
 
Table 3 
Key Points 
Neuropsychiatric disorders are common in MS, especially depression and cognitive impairment which affect around 50% of 
individuals at some point. 
They can occur at any time in the disease process but are rarely the first presenting symptom. 
Untreated neuropsychiatric symptoms result in worse social and occupational function and reduced quality of life. 
Neuropsychiatric are under-recognised but appropriate screening and diagnostic tools are available. 
There should be close liaison between psychiatry and neurology teams to achieve holistic management of these disorders. 
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